Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Issues Quarterly Earnings Results

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) posted its quarterly earnings results on Wednesday. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.21, FiscalAI reports. The business had revenue of $2.51 million during the quarter, compared to the consensus estimate of $0.40 million.

Armata Pharmaceuticals Trading Up 1.4%

Shares of NYSEAMERICAN:ARMP traded up $0.06 during trading on Wednesday, reaching $4.31. 126,433 shares of the company traded hands, compared to its average volume of 92,798. Armata Pharmaceuticals has a 52-week low of $2.39 and a 52-week high of $16.34. The firm has a market capitalization of $158.22 million, a price-to-earnings ratio of -0.55 and a beta of 1.30. The business’s fifty day moving average is $5.77 and its 200-day moving average is $8.15.

Institutional Investors Weigh In On Armata Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARMP. Jane Street Group LLC purchased a new stake in Armata Pharmaceuticals during the 4th quarter valued at $108,000. Millennium Management LLC purchased a new position in shares of Armata Pharmaceuticals in the fourth quarter valued at about $164,000. OMERS ADMINISTRATION Corp bought a new position in shares of Armata Pharmaceuticals during the fourth quarter valued at about $177,000. Goldman Sachs Group Inc. bought a new position in shares of Armata Pharmaceuticals during the fourth quarter valued at about $284,000. Finally, State Street Corp boosted its holdings in shares of Armata Pharmaceuticals by 26.1% during the fourth quarter. State Street Corp now owns 50,800 shares of the company’s stock worth $319,000 after purchasing an additional 10,500 shares during the period. 3.57% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Zacks Research raised Armata Pharmaceuticals to a “hold” rating in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $15.00.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.